Long-Term Treatment With an IDH Inhibitor: What Life Can Look Like Years Down the Road

Doctors often describe this experience in very concrete terms: people coming to clinic visits who feel well, whose disease remains controlled, and who are continuing the same pill they started long ago. For patients diagnosed with a brain tumor, where treatment has historically meant surgery followed quickly by radiation and chemotherapy, this represents a fundamentally different trajectory.

Years on treatment—and still benefiting

The earliest patients who participated in the initial clinical trials of IDH inhibitors did so nearly a decade ago. Some of those individuals have now been on the same medication for nine or ten years. In a subset of patients, the drug is still doing exactly what it was intended to do: keeping the tumor quiet.

That does not mean the tumor is gone. IDH inhibitors are not curative. But for many people, the medication has acted as a long-term disease control strategy: slowing or halting growth for extended periods while preserving quality of life.

This long duration of benefit is significant in IDH-mutant glioma, which often affects younger adults who may otherwise be facing years of cumulative treatment-related side effects. The ability to maintain stability while continuing to live fully is one of the reasons experts consider IDH inhibitors a major advance.

What Long-Term Treatment Actually Feels Like

Patients often ask what it is like to stay on an IDH inhibitor for years. For most, the experience resembles managing a chronic condition such as diabetes or hypertension rather than undergoing intensive cancer therapy.

These drugs are taken orally, typically once or twice daily. Side effects are usually mild compared with traditional chemotherapy, and many patients report that after an initial adjustment period, the medication fades into the background of daily life. Regular follow-up visits and MRI scans remain essential, but between appointments, many people are able to focus on work, family, and personal goals.

Importantly, long-term use has not revealed the kind of cumulative toxicity that doctors often worry about with other cancer treatments. That reassurance has grown stronger as more patients reach multi-year milestones on therapy.

Can Someone Ever Stop Taking an IDH Inhibitor?

This is one of the most common, and most emotionally charged questions patients ask.

At this point, weaning someone off an IDH inhibitor is very challenging, and in most cases, not recommended. Even when the tumor has been stable for years, the underlying biology has not been erased. The cancer remains present at a microscopic level, and there is always concern about regrowth if treatment is stopped.

“Even though we have a very effective treatment right now, the tumors remain incurable. And so we always worry about the risk of regrowth,” says Dr. Botero. “And so, even though we now have a fantastic option that allows us to prolong the time that patients feel well, ultimately we know that eventually patients will still need the standard treatments of chemotherapy and radiation.”

From a medical standpoint, continuing the drug is often viewed as the safer option, especially when it is well tolerated and clearly effective. Doctors weigh the benefits of ongoing disease control against the uncertainty of what might happen if the medication is withdrawn.

In other words, the goal is not to “finish” IDH inhibitor therapy in the way one finishes a short course of chemotherapy. Instead, it is often used as long-term management, similar to how some chronic illnesses are treated with ongoing medication.

A Powerful Bridge, Not the Final Destination

Even with these encouraging long-term outcomes, it is important to be clear about the limits of current therapy. IDH inhibitors have changed the timeline of treatment, but they have not eliminated the need for standard approaches altogether.

Most experts believe that many patients will still eventually require radiation and/or chemotherapy at some point in their disease course. The difference is that IDH inhibitors may significantly delay when those treatments are needed—and allow patients to approach them later, often with better neurologic function and quality of life.

In that sense, IDH inhibitors act as a powerful bridge. They extend the period during which patients feel well, remain active, and avoid therapies that can carry long-term cognitive or physical side effects.

Questions You May Want to Ask Your Doctor

• How long do you expect I might stay on an IDH inhibitor if it continues to work?
• What signs would suggest the drug is no longer effective?
• Are there long-term side effects we should be monitoring for?
• How does staying on this medication affect the timing of radiation or chemotherapy?

Learn more about SurvivorNet's rigorous medical review process.

---